Fig. 3: miR-125a-5p slows the progression of MCT-PAH. | Experimental & Molecular Medicine

Fig. 3: miR-125a-5p slows the progression of MCT-PAH.

From: MiR-125a-5p ameliorates monocrotaline-induced pulmonary arterial hypertension by targeting the TGF-β1 and IL-6/STAT3 signaling pathways

Fig. 3

The miR-125a-5p agomir (1 nM or 2 nM) was administered by nebulizer, and mRVP, SPAP, and the Fulton index were measured 3 weeks (a) or 4 weeks (b) after MCT injection (n = 5–6 rats per group). AGO, miR-125a-5p agomir; mRVP, mean right ventricular pressure; SPAP, systolic pulmonary arterial pressure. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 vs. control; #p < 0.05, ##p < 0.01, and ####p < 0.0001 vs. MCT-WK3

Back to article page